A retrospective study found dose-dense AC with pembrolizumab was feasible in TNBC, without more neutropenia or missed immunotherapy doses.
Samantha Hodges, PharmD; Katelyn Patterson, PharmD, et al.
September 8, 2026
Recent Updates
The latest breakthroughs, research highlights, and industry developments in oncology.
View More
FDA Approvals
Updates on recent FDA approvals, label expansions, and regulatory decisions that may affect everyday oncology practice.
View More
Clinical Trials
Stay current on pivotal oncology trials with practice-changing results, recruiting studies, and key readouts relevant to community cancer care.
View More
Clinical Trials
Samantha Hodges, PharmD; Katelyn Patterson, PharmD, et al.
September 8, 2026
